Macquarie Group Ltd. reduced its stake in shares of AstraZeneca plc (NYSE:AZN) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 510,800 shares of the company’s stock after selling 40,700 shares during the quarter. Macquarie Group Ltd.’s holdings in AstraZeneca were worth $17,725,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. Wells Fargo & Company MN grew its position in AstraZeneca by 7.6% during the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after buying an additional 310,389 shares during the period. Point72 Asset Management L.P. grew its position in AstraZeneca by 103.1% during the third quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after buying an additional 621,831 shares during the period. Zions Bancorporation grew its position in AstraZeneca by 2,719.4% during the third quarter. Zions Bancorporation now owns 38,852 shares of the company’s stock worth $1,317,000 after buying an additional 37,474 shares during the period. Ingalls & Snyder LLC acquired a new position in AstraZeneca during the fourth quarter worth about $865,000. Finally, BB&T Investment Services Inc. grew its position in AstraZeneca by 54.9% during the third quarter. BB&T Investment Services Inc. now owns 23,136 shares of the company’s stock worth $782,000 after buying an additional 8,199 shares during the period. Institutional investors own 15.13% of the company’s stock.
Shares of AstraZeneca stock opened at $34.17 on Friday. The company has a market cap of $86,549.05, a P/E ratio of 14.42, a PEG ratio of 1.77 and a beta of 0.71. AstraZeneca plc has a 1 year low of $28.43 and a 1 year high of $36.70. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62.
The firm also recently declared a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were given a $0.95 dividend. The ex-dividend date was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is presently 57.81%.
Several brokerages have weighed in on AZN. BMO Capital Markets set a $40.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Thursday. Leerink Swann upped their target price on shares of AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 6th. Sanford C. Bernstein upped their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. ValuEngine lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 7th. Finally, Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $36.32.
WARNING: “AstraZeneca plc (AZN) Holdings Trimmed by Macquarie Group Ltd.” was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299840/astrazeneca-plc-azn-holdings-trimmed-by-macquarie-group-ltd.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.